Nivolumab in Lung Cancer

Get Permission

I find The ASCO Post to be a good way to hear about new ideas that I might otherwise have missed. I read an article recently about the approval of nivolumab (Opdivo) for treating metastatic squamous non-small cell lung cancer (The ASCO Post, April 10, 2015). I thought it would have been much more useful if a reference to the published trial data or presentation was provided, but then learned that no such data had yet been published in a peer-reviewed journal or presented at a major oncology conference, like ASCO or ESMO (European Society of Medical Oncology). It is my hope that no oncologist would prescribe a new drug without seeing the published literature. ■

—Philip Champion MD, FRCPC

Charlottetown, PE, C1A 8T5, Canada


Related Articles

The ASCO Post Replies

Nivolumab (Opdivo) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of lung cancer on March 4, 2015, before clinical data from the pivotal trials (CheckMate 017 and CheckMate 063) were presented at a major oncology conference or published in a peer-reviewed journal....




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.